• 1
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 16161634.
  • 2
    Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. In: MurphyMJJr., editor. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Dayton: AlphaMed Press, 1991: 121142.
  • 3
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998; 16: 34123425.
  • 4
    Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94: 12111220.
  • 5
    Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997; 34(3 Suppl 2 ): 1319.
  • 6
    Elliot S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003; 21: 414421.
  • 7
    Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10: 23922395.
  • 8
    Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002; 87: 268276.
  • 9
    Henry DH. Optimizing the treatment of anemia in cancer patients. Oncology. 2002; 16: 912.
  • 10
    Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Oncology. 2002; 16: 3136.
  • 11
    Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumors receiving chemotherapy: results of a double-blind, placebo-controlled, randomized study. Eur J Cancer. 2003; 39: 20262034.
  • 12
    Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of anemia during cancer chemotherapy. Cancer. 2003; 97: 13121320.
  • 13
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002; 20: 40834107.
  • 14
    Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19: 28752882.
  • 15
    Jumbe NL, Rossi G, Heatherington AC. The science of erythropoiesis: quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamics (PD) modeling [abstract]. Blood. 2002; 100: 9b.
  • 16
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin Alfa Study Group. J Clin Oncol. 2001; 19: 28652874.
  • 17
    Amgen Inc. Aranesp® [package insert]. Thousand Oaks: Amgen Inc., 2002.